185 related articles for article (PubMed ID: 23543223)
1. Tumour vasculature targeting agents in hybrid/conjugate drugs.
Prokopiou EM; Ryder SA; Walsh JJ
Angiogenesis; 2013 Jul; 16(3):503-24. PubMed ID: 23543223
[TBL] [Abstract][Full Text] [Related]
2. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
3. The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.
Head M; Jameson MB
Expert Opin Investig Drugs; 2010 Feb; 19(2):295-304. PubMed ID: 20050824
[TBL] [Abstract][Full Text] [Related]
4. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
Leite de Oliveira R; Hamm A; Mazzone M
Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
[TBL] [Abstract][Full Text] [Related]
5. Modelling approaches for angiogenesis.
Taraboletti G; Giavazzi R
Eur J Cancer; 2004 Apr; 40(6):881-9. PubMed ID: 15120043
[TBL] [Abstract][Full Text] [Related]
6. Design and development of polymer conjugates as anti-angiogenic agents.
Segal E; Satchi-Fainaro R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenesis in cancer therapy: Hercules and hydra.
Bellou S; Pentheroudakis G; Murphy C; Fotsis T
Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856
[TBL] [Abstract][Full Text] [Related]
8. Selective targeting of the tumour vasculature.
Chan LS; Daruwalla J; Christophi C
ANZ J Surg; 2008 Nov; 78(11):955-67. PubMed ID: 18959693
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery.
Bouzin C; Feron O
Drug Resist Updat; 2007 Jun; 10(3):109-20. PubMed ID: 17452119
[TBL] [Abstract][Full Text] [Related]
10. Limiting supply.
Nat Rev Cancer; 2008 Aug; 8(8):577. PubMed ID: 18672479
[TBL] [Abstract][Full Text] [Related]
11. Tumour vascular targeting.
Neri D; Bicknell R
Nat Rev Cancer; 2005 Jun; 5(6):436-46. PubMed ID: 15928674
[TBL] [Abstract][Full Text] [Related]
12. Anticancer therapeutics: "Addictive" targets, multi-targeted drugs, new drug combinations.
Broxterman HJ; Georgopapadakou NH
Drug Resist Updat; 2005 Aug; 8(4):183-97. PubMed ID: 16154800
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis: an update and potential drug approaches (review).
Abdelrahim M; Konduri S; Basha R; Philip PA; Baker CH
Int J Oncol; 2010 Jan; 36(1):5-18. PubMed ID: 19956828
[TBL] [Abstract][Full Text] [Related]
14. [A new treatment protocol targeting tumor vasculature--- metronomic chemotherapy combined radiotherapy].
Qiu H; Wang GM
Ai Zheng; 2007 Dec; 26(12):1392-6. PubMed ID: 18076810
[TBL] [Abstract][Full Text] [Related]
15. Microtubule-targeting agents in angiogenesis: where do we stand?
Pasquier E; Honoré S; Braguer D
Drug Resist Updat; 2006; 9(1-2):74-86. PubMed ID: 16714139
[TBL] [Abstract][Full Text] [Related]
16. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenesis and vascular disrupting agents in cancer: circumventing resistance and augmenting their therapeutic utility.
Close A
Future Med Chem; 2016; 8(4):443-62. PubMed ID: 26933926
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic therapies in cancer: achievements and open questions.
Ruegg C; Mutter N
Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in tumor vasculature targeting using liposomal drug delivery systems.
Abu Lila AS; Ishida T; Kiwada H
Expert Opin Drug Deliv; 2009 Dec; 6(12):1297-309. PubMed ID: 19780711
[TBL] [Abstract][Full Text] [Related]
20. Vascular targeting therapy: potential benefit depends on tumor and host related effects.
Horsman MR; Bohn AB; Busk M
Exp Oncol; 2010 Sep; 32(3):143-8. PubMed ID: 21403608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
